Mindset Pharma has announced that it has developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central nervous system (CNS) penetration of first and subsequent generations of psychedelic medicines. The proof of concept of this novel formulation demonstrates improved CNS penetration compared to standard formulations of 5-MeO-DMT.
Category Press Release
Published in GlobeNewswire
Companies Featured
Mindset PharmaMindset Pharma is a Toronto-based drug discovery company that aims to develop novel psychedelic drugs.